Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Diabetes Res Clin Pract. 2019 Oct 24;158:107894. doi: 10.1016/j.diabres.2019.107894

TABLE 2.

The relationships of diabetic ketoacidosis, C-peptide and autoantibodies for 81 T1D subjects.

C-peptide status Autoantibody status
<0.13 nmol/L (<0.4 ng/mL) 0.13–0.23 nmol/L (0.4–0.7 ng/mL) 0.26–1.03 nmol/L (0.8–3.1 ng/mL)1 GAD-65 ≥30 IU/m IA2 ≥30 IU/m Both autoantibodies Either/both autoantibodies Neither autoantibody
Diabetic Ketoacidosis (n = 8) (9.5%) 0 (0%) 1 (12.5%) 7 (87.5%) 3 (37.5%) 2 (25.0%) 1 (12.5%) 4 (50.0%) 4 (50.0%)
C-peptide <0.13 nmol/L (<0.4 ng/mL) (n = 5) 2 (40.0%) 1 (20.0) 1 (20.0%) 2 (40.0%) 3 (60.0%)
C-peptide 0.13–0.23 nmol/L (0.4–0.7 ng/mL) (n = 8) 1 (12.5%) 1 (12.5%) 0 (0%) 2 (25.0%) 6 (75.0%)
C-peptide 0.26–1.03 nmol/L (0.8–3.1 ng/mL)1 (n = 68) 19 (27.9%) 7 (10.3%) 4 (5.9%) 21 (30.9%) 46 (67.6%)
1:

Normal range. No T1D subjects had C-peptide values >1.03 nmol/L (>3.1 ng/mL).